Published in Pediatr Crit Care Med on September 01, 2011
The potential for bio-mediators and biomarkers in pediatric traumatic brain injury and neurocritical care. Front Neurol (2013) 0.91
Proteomic profiling of the retinas in a neonatal rat model of oxygen-induced retinopathy with a reproducible ion-current-based MS1 approach. J Proteome Res (2015) 0.80
Biomarkers in psychiatry: how close are we? Front Psychiatry (2013) 0.79
Glial fibrillary acidic protein as a brain injury biomarker in children undergoing extracorporeal membrane oxygenation. Pediatr Crit Care Med (2011) 2.02
In the wake of the 2003 and 2011 duty hours regulations, how do internal medicine interns spend their time? J Gen Intern Med (2013) 3.03
Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron (2002) 2.48
Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med (2010) 2.44
Structure of the Nogo receptor ectodomain: a recognition module implicated in myelin inhibition. Neuron (2003) 2.06
Genetic and functional dissection of HTRA1 and LOC387715 in age-related macular degeneration. PLoS Genet (2010) 1.83
Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care (2011) 1.68
Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med (2011) 1.65
Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma (2007) 1.58
Morphologic and biochemical characterization of brain injury in a model of controlled blast overpressure exposure. J Trauma (2010) 1.49
Mechanics and dynamics of the strain-induced M1-M2 structural phase transition in individual VO₂ nanowires. Nano Lett (2011) 1.42
Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm (2009) 1.36
Common data elements for traumatic brain injury: recommendations from the biospecimens and biomarkers working group. Arch Phys Med Rehabil (2010) 1.35
Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention. J Trauma Acute Care Surg (2012) 1.34
Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol (2008) 1.31
Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J Neurotrauma (2011) 1.31
Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats. Eur J Neurosci (2010) 1.28
Novel differential neuroproteomics analysis of traumatic brain injury in rats. Mol Cell Proteomics (2006) 1.28
Calpain-mediated collapsin response mediator protein-1, -2, and -4 proteolysis after neurotoxic and traumatic brain injury. J Neurotrauma (2007) 1.26
αII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma (2010) 1.26
Neuroprotection targets after traumatic brain injury. Curr Opin Neurol (2006) 1.23
Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab (2004) 1.18
Serum concentrations of ubiquitin C-terminal hydrolase-L1 and αII-spectrin breakdown product 145 kDa correlate with outcome after pediatric TBI. J Neurotrauma (2012) 1.18
Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis. Biochem J (2006) 1.18
Calpain and caspase processing of caspase-12 contribute to the ER stress-induced cell death pathway in differentiated PC12 cells. Apoptosis (2010) 1.16
Biomarkers of blast-induced neurotrauma: profiling molecular and cellular mechanisms of blast brain injury. J Neurotrauma (2009) 1.15
Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury. Neurosurgery (2012) 1.14
Proteomic identification of biomarkers of traumatic brain injury. Expert Rev Proteomics (2005) 1.14
Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis (2009) 1.12
Biochemical, structural, and biomarker evidence for calpain-mediated cytoskeletal change after diffuse brain injury uncomplicated by contusion. J Neuropathol Exp Neurol (2009) 1.12
alphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. J Neurotrauma (2009) 1.11
Assessing susceptibility to age-related macular degeneration with genetic markers and environmental factors. Arch Ophthalmol (2011) 1.10
Blood-based diagnostics of traumatic brain injuries. Expert Rev Mol Diagn (2011) 1.10
Brain injury biomarkers may improve the predictive power of the IMPACT outcome calculator. J Neurotrauma (2012) 1.10
Neuro-glial and systemic mechanisms of pathological responses in rat models of primary blast overpressure compared to "composite" blast. Front Neurol (2012) 1.10
Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury. J Neurotrauma (2012) 1.09
Serum biomarkers of MRI brain injury in neonatal hypoxic ischemic encephalopathy treated with whole-body hypothermia: a pilot study. Pediatr Crit Care Med (2013) 1.07
Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injury. J Neurochem (2006) 1.07
GFAP out-performs S100β in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions. J Neurotrauma (2014) 1.05
Use of biomarkers for diagnosis and management of traumatic brain injury patients. Expert Opin Med Diagn (2008) 1.02
Serum brain biomarker level, neurocognitive performance, and self-reported symptom changes in soldiers repeatedly exposed to low-level blast: a breacher pilot study. J Neurotrauma (2013) 1.01
Increased expression and processing of caspase-12 after traumatic brain injury in rats. J Neurochem (2004) 1.01
Delayed increases in microvascular pathology after experimental traumatic brain injury are associated with prolonged inflammation, blood-brain barrier disruption, and progressive white matter damage. J Neurotrauma (2014) 1.00
Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs. J Med Chem (2010) 0.98
Assessing neuro-systemic & behavioral components in the pathophysiology of blast-related brain injury. Front Neurol (2013) 0.97
Biomarkers of proteolytic damage following traumatic brain injury. Brain Pathol (2004) 0.97
Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial. J Neurotrauma (2009) 0.95
Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients. Mol Med (2011) 0.94
Amino acid starvation induced autophagic cell death in PC-12 cells: evidence for activation of caspase-3 but not calpain-1. Apoptosis (2006) 0.94
NMDA receptor antagonist felbamate reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat. J Neurotrauma (2007) 0.94
Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure. BMC Neurol (2012) 0.94
Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. Eur J Pharmacol (2011) 0.92
Alpha-II spectrin breakdown products in aneurysmal subarachnoid hemorrhage: a novel biomarker of proteolytic injury. J Neurosurg (2007) 0.91
Changes in autophagy proteins in a rat model of controlled cortical impact induced brain injury. Biochem Biophys Res Commun (2008) 0.91
Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: a microdialysis study. Acta Neurochir (Wien) (2008) 0.90
Alpha II-spectrin breakdown products serve as novel markers of brain injury severity in a canine model of hypothermic circulatory arrest. Ann Thorac Surg (2009) 0.90
Unfolded protein response after neurotrauma. J Neurotrauma (2006) 0.90
Temperature-gated thermal rectifier for active heat flow control. Nano Lett (2014) 0.89
Increased expression of tissue-type transglutaminase following middle cerebral artery occlusion in rats. J Neurochem (2004) 0.89
Dual vulnerability of tau to calpains and caspase-3 proteolysis under neurotoxic and neurodegenerative conditions. ASN Neuro (2011) 0.89
Degradation of βII-Spectrin Protein by Calpain-2 and Caspase-3 Under Neurotoxic and Traumatic Brain Injury Conditions. Mol Neurobiol (2014) 0.89
A novel multicenter preclinical drug screening and biomarker consortium for experimental traumatic brain injury: operation brain trauma therapy. J Trauma (2011) 0.89
Direct Rho-associated kinase inhibition [correction of inhibiton] induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells. Cell Mol Biol Lett (2006) 0.89
Systems biology, bioinformatics, and biomarkers in neuropsychiatry. Front Neurosci (2012) 0.89
Acute NMDA toxicity in cultured rat cerebellar granule neurons is accompanied by autophagy induction and late onset autophagic cell death phenotype. BMC Neurosci (2010) 0.88
Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometry. J Neurochem (2007) 0.88
Poorly differentiated clusters (PDCs) as a novel histological predictor of nodal metastases in pT1 colorectal cancer. Virchows Arch (2014) 0.88
Proteomics studies of traumatic brain injury. Int Rev Neurobiol (2004) 0.87
Cell-specific DNA fragmentation may be attenuated by a survivin-dependent mechanism after traumatic brain injury in rats. Exp Brain Res (2005) 0.87
Decoupling of structural and electronic phase transitions in VO2. Phys Rev Lett (2012) 0.87
Cell-specific upregulation of survivin after experimental traumatic brain injury in rats. J Neurotrauma (2004) 0.87
Calpain- and caspase-mediated alphaII-spectrin and tau proteolysis in rat cerebrocortical neuronal cultures after ecstasy or methamphetamine exposure. Int J Neuropsychopharmacol (2006) 0.87
Leveraging biomarker platforms and systems biology for rehabilomics and biologics effectiveness research. PM R (2011) 0.86
Concurrent calpain and caspase-3 mediated proteolysis of alpha II-spectrin and tau in rat brain after methamphetamine exposure: a similar profile to traumatic brain injury. Life Sci (2005) 0.86
Molecular cloning and characterization of rat and human calpain-5. Biochem Biophys Res Commun (2004) 0.86
Combining biochemical and imaging markers to improve diagnosis and characterization of mild traumatic brain injury in the acute setting: results from a pilot study. PLoS One (2013) 0.86
Increased levels of serum MAP-2 at 6-months correlate with improved outcome in survivors of severe traumatic brain injury. Brain Inj (2012) 0.86
Detection of protein biomarkers using high-throughput immunoblotting following focal ischemic or penetrating ballistic-like brain injuries in rats. Brain Inj (2008) 0.85
P43/pro-EMAPII: a potential biomarker for discriminating traumatic versus ischemic brain injury. J Neurotrauma (2009) 0.85
Systems biology and theranostic approach to drug discovery and development to treat traumatic brain injury. Methods Mol Biol (2010) 0.85
Biomarkers track damage after graded injury severity in a rat model of penetrating brain injury. J Neurotrauma (2013) 0.85
Neuroproteomics: a biochemical means to discriminate the extent and modality of brain injury. J Neurotrauma (2010) 0.84
Up-regulation of tissue-type transglutaminase after traumatic brain injury. J Neurochem (2002) 0.84
Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry. J Neurotrauma (2005) 0.84
A multidimensional differential proteomic platform using dual-phase ion-exchange chromatography-polyacrylamide gel electrophoresis/reversed-phase liquid chromatography tandem mass spectrometry. Anal Chem (2005) 0.84
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options. Nutr Cancer (2014) 0.84
Galveston Brain Injury Conference 2010: clinical and experimental aspects of blast injury. J Neurotrauma (2012) 0.84
Temporal and spatial profile of Bid cleavage after experimental traumatic brain injury. J Cereb Blood Flow Metab (2002) 0.83
Ecstasy toxicity: a comparison to methamphetamine and traumatic brain injury. J Addict Dis (2006) 0.83
Cerebrospinal fluid biomarker candidates for parkinsonian disorders. Front Neurol (2013) 0.83
Cerebrospinal fluid protein biomarker panel for assessment of neurotoxicity induced by kainic acid in rats. Toxicol Sci (2012) 0.83
Giant-amplitude, high-work density microactuators with phase transition activated nanolayer bimorphs. Nano Lett (2012) 0.83
Neuroproteomics and systems biology-based discovery of protein biomarkers for traumatic brain injury and clinical validation. Proteomics Clin Appl (2008) 0.83
Lysophosphatidic acid induces clonal generation of mouse neurospheres via proliferation of Sca-1- and AC133-positive neural progenitors. Stem Cells Dev (2004) 0.83
Novel neuroproteomic approaches to studying traumatic brain injury. Prog Brain Res (2007) 0.83